Chemotherapy Options for Blastic Plasmacytoid Dendritic Cell Neoplasm

Michael Haddadin, Justin Taylor

Research output: Contribution to journalReview articlepeer-review

4 Scopus citations


BPDCN is ultimately a bone marrow disease requiring induction-type eradication therapy followed by hematopoietic stem cell transplant (HSCT) to achieve long-lasting remissions or cure. Various regimens have been applied to this disease with varying success. A cumulative review of the literature suggests more intense regimens have greater efficacy with acute lymphoblastic leukemia regimens preferred to acute myeloid leukemia regimens. This approach benefits fit patients who are eligible for HSCT; however, most BPDCN patients require other treatment options. The recent FDA approval of the CD123-targeted agent tagraxofusp provides a novel therapeutic alternative to traditional chemotherapy but with potential toxicities.

Original languageEnglish (US)
Pages (from-to)539-552
Number of pages14
JournalHematology/Oncology Clinics of North America
Issue number3
StatePublished - Jun 2020
Externally publishedYes


  • Chemotherapy
  • Induction
  • Low-intensity

ASJC Scopus subject areas

  • Hematology
  • Oncology


Dive into the research topics of 'Chemotherapy Options for Blastic Plasmacytoid Dendritic Cell Neoplasm'. Together they form a unique fingerprint.

Cite this